Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03442101 · ClinicalTrials.gov registry record
Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study
A clinical trial of Psychosis, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- 156
- Enrollment target
- 1
- Study location
NCT03442101: Active study of Psychosis, sponsored by University of Alabama at Birmingham.
NCT03442101 is a study of Psychosis that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 156 participants, below the 174-participant average among 35 other Psychosis trials with a reported enrollment target (10% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03442101, a study of Psychosis, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- 156 participants
- Enrollment target
- 1
- Study location
Study Summary
Psychosis is a heterogeneous disorder and present treatment only works for a limited number of patients. In order to identify new therapeutic targets, this study will longitudinally characterize the underlying pathologies in those with poor treatment response using complimentary brain imaging modalities.
Primary Outcome
Measures of brain structure, as measured with diffusion tensor imaging (DTI) that are associated at baseline (when patients are unmedicated) with subsequent treatment response to antipsychotic medication.
Conditions Studied
Interventions
- DRUG Patients with psychosis will be treated with known antipsychotic medication
Study Locations (1)
Alabama
- Sparks Center - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2018-04-01 |
| Est. Completion | 2026-12-31 |
What the registry record for NCT03442101 still lists
NCT03442101 is an observational study that tracks outcomes without assigning an intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, below the 174-participant average among 35 other Psychosis trials with a reported enrollment target (10% lower).
The record links to 1 condition, with Psychosis appearing as the primary indexed condition, and to 1 intervention - of which Patients with psychosis will be treated with known antipsychotic medication is the first listed.
NCT03442101 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT03442101 about?
NCT03442101 is a clinical study titled "Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study". Psychosis is a heterogeneous disorder and present treatment only works for a limited number of patients. In order to identify new therapeutic targets, this study will longitudinally characterize the underlying pathologies in those with poor treatment response using complimentary brain imaging modali...
What is the current status of trial NCT03442101?
This trial is currently active not recruiting. The enrollment target is 156 participants. The study started on 2018-04-01. Estimated completion is 2026-12-31.
What conditions does trial NCT03442101 study?
This clinical trial studies the following conditions: Psychosis.
What interventions are being tested in trial NCT03442101?
The interventions under investigation include: Patients with psychosis will be treated with known antipsychotic medication (DRUG).
Who is sponsoring clinical trial NCT03442101?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03442101 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psychosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03442101's enrollment target sits among peer trials
156 7th of 35 higher than 29 of 35 other Psychosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psychosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults
RECRUITING · NA
-
Determining the Role of Social Reward Learning in Social Anhedonia
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia
RECRUITING · NA
-
Acute Psychiatric Care at Home for Lower-risk Patients With Acute Psychiatric Illness Who Require Inpatient Care
RECRUITING · NA
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI